Siemens Healthineers (OTCMKTS:SMMNY) Upgraded at Zacks Research

Siemens Healthineers (OTCMKTS:SMMNY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also recently weighed in on SMMNY. Royal Bank Of Canada initiated coverage on Siemens Healthineers in a research report on Wednesday, December 17th. They set a “moderate buy” rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research report on Thursday, December 4th. Three investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Siemens Healthineers presently has an average rating of “Buy”.

Siemens Healthineers Stock Down 0.7%

Siemens Healthineers stock opened at $27.17 on Monday. Siemens Healthineers has a 12 month low of $23.28 and a 12 month high of $30.19. The stock’s 50 day moving average is $25.55 and its 200-day moving average is $26.85.

About Siemens Healthineers

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.